

Department of Pharmacology and Experimental Department of Pharmacology and Experimental Therapeutics Posters Therapeutics

10-23-2015

Ethanol Pharmacokinetics in Neonates Secondary to Medication Administration

Elizabeth Marek, PharmD Thomas Jefferson University

Susan C. Adeniyi-Jones, MD *Thomas Jefferson University*

Lindsey Roke, PharmD Thomas Jefferson University

Tara E. DeCerbo, PharmD Thomas Jefferson University

Rebecca L. Cordell, PharmD Follow this and additional works at: https://jdc.jefferson.edu/petposters

🔮 Part of the Pharmacy and Pharmaceutical Sciences Commons

Let us know how access to this document benefits you

Recommended Citation

Marek, PharmD, Elizabeth; Adeniyi-Jones, MD, Susan C.; Roke, PharmD, Lindsey; DeCerbo, PharmD, Tara E.; Cordell, PharmD, Rebecca L.; Monks, PharmD, Paul S.; and Kraft, MD, Walter K., "Ethanol Pharmacokinetics in Neonates Secondary to Medication Administration" (2015). *Department of Pharmacology and Experimental Therapeutics Posters*. 1.

https://jdc.jefferson.edu/petposters/1

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Posters by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Elizabeth Marek, PharmD; Susan C. Adeniyi-Jones, MD; Lindsey Roke, PharmD; Tara E. DeCerbo, PharmD; Rebecca L. Cordell, PharmD; Paul S. Monks, PharmD; and Walter K. Kraft, MD



Ethanol Pharmacokinetics in Neonates Secondary to Medication Administration

Elizabeth Marek¹, Susan C. Adeniyi-Jones², Lindsey Roke³, Tara E. DeCerbo³, Rebecca L. Cordell⁴, Paul S. Monks⁴ and Walter K. Kraft¹

¹Department of Pharmacology & Experimental Therapeutics, Division of Clinical Pharmacology, Thomas Jefferson University, Philadelphia, PA; ²Department of Pediatrics, Thomas Jefferson University/Nemours Children's Clinics; Philadelphia, PA; ³Department of Pharmacy, Thomas Jefferson University Hospital, PA; ⁴Department of Chemistry, University of Leicester, Leicester, United Kingdom

Abstract

Purpose:


Ethanol serves as a solvent and microbial preservative in oral liquid medications and is the second most commonly used solvent in liquid medications following water. Despite widespread use of ethanol in liquid medications for neonates, the pharmacokinetics and toxicity of ethanol in young children are not well described. The aim of the current study is to quantify blood ethanol levels in neonates secondary to oral ethanol containing medications. Methods:

Neonates who received either oral phenobarbital (15% ethanol) and/or oral dexamethasone (30% ethanol) per standard of care were eligible for enrollment. A maximum of 6 blood samples per patient (4.5 mL total) were taken over the study period. Blood samples were collected via heel stick at the time of clinical laboratory collections or following a specific collection for study purposes. In addition, blood samples were collected from neonates receiving sublingual buprenorphine (30% ethanol) for neonatal abstinence syndrome from a separate clinical study. Blood ethanol levels were measured using a validated headspace gas chromatography-mass spectrometry method utilizing micro-volume (~100uL) plasma samples. The limit of detection and lower limit of quantification for the assay were 0.1 mg/L and 0.5 mg/L respectively.

Results:

A total of 39 plasma samples from 15 neonates who were on ethanol containing medications were collected over the study period. Four neonates were exposed to phenobarbital and/or dexamethasone, while eleven neonates were exposed to buprenorphine alone or in combination with phenobarbital. Patients were exposed to an average of 71.6 mg/kg (range 13.1 to 215 mg/kg) of ethanol after a single dose of an ethanol containing medication. Blood ethanol levels were detectable in 98% (38/39) of samples, quantifiable in 67% (26/39) of samples, and ranged from below detection to 85.4 mg/L. Ethanol was rapidly cleared and did not accumulate with current dosing regimens. **Conclusion:**

Ethanol intake secondary to medication administration varied widely. Blood ethanol levels in neonates were low and ethanol was eliminated rapidly after a single dose of oral medications that contained a sizable fraction of ethanol.



absorption, distribution, metabolism, and excretion of ethanol in neonates when compared to adults. Figure reproduced from: Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res Clin Exp. 2014 Oct 22;76:90-7

Organization	Year	Recommendation
American Academy of Pediatrics ¹	1984	Blood ethanol levels should not exceed 250mg/L following a single dose of an alcohol containing medication
Code of Federal Regulations, 21 CFR 328	1995	Any over the counter product shall not contain >0.5% alcohol as an inactive ingredient in children <6 years
European Medicines Agency ²	2014	Blood ethanol levels should not exceed 10mg/L in children <6 years of age


Figure 2. Recommended ethanol limits for pediatrics. The American Academy of Pediatrics, Food and Drug Administration, and European Medicines Agency have all taken action, by either setting limits of ethanol content in over-the-counter medications or by recommending restricted exposure to ethanol containing pediatric formulations.

Committee for Human Medicinal Products (CHMP). Questions and answers on ethanol in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products fo human use' (CPMP/463/0

1. Ethanol in liquid preparations intended for children. Pediatrics. 1984 Mar;73(3):405-7.



	Me	ethods			Endo I
Samples were co	ollected from two po	opulations:			
ethanol, q12h standard of ca samples/patie collected via h following a sp • Inc	and/or oral dexar are were eligible for ent were taken over neel stick at the time ecific collection for	eceived either oral phenobarbinethasone (30% ethanol, q12 enrollment. A maximum of 6 the study period. Blood samp e of clinical laboratory collecti study purposes. <1 year, on any oral ethanol co	hr) per blood oles were ons or	4.9 4 3.5 3 2.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1	
q8hr) or mor syndrome (NA • Inc	phine (n=14, contro AS) from a separate o Iusion Criteria: ≥37	lingual buprenorphine (n=12, l, no ethanol) for neonatal abs clinical study (NCT01452789). weeks gestation, exposure to oms of NAS requiring treatme	stinence opiates in	-0.5	0 5 10 Count
Blood ethano	l levels were measu	red using a validated headspa	ce gas	• 4	0% of the sampl 3% of the sampl
plasma sampl	es. The limit of dete	ection (LOD) and lower limit o ly were 0.1 mg/L and 0.5 mg/l	of	figure from 2 who w	3. Endogenous 14 neonates). So vere on morphin ations.
				1	lones AW, Mårdh G, Angg chromatography-mass
		Mean ± SD or Number			
	Characteristic	Phenobarbital or Dexamethasone "Ethanol"		Characte	ristic
	Characteristic Birth weight (g)	Phenobarbital or Dexamethasone		Characte Birth weig	
		Phenobarbital or Dexamethasone "Ethanol" (n=3)			ht (g)
	Birth weight (g) Gestational age (wk) Postnatal age (day)	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1		Birth weig	ht (g) age (wk)
	Birth weight (g) Gestational age (wk)	Phenobarbital or Dexamethasone "Ethanol" (n=3)1858 ± 1540.131.1 ± 5.9		Birth weig Gestational a	ht (g) age (wk) ge (day)
	Birth weight (g) Gestational age (wk) Postnatal age (day)	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex $2/1$		Birth weig Gestational a Postnatal ag	ht (g) age (wk) ge (day) I age (wk)
	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk)	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex		Birth weig Gestational a Postnatal ag Postmenstrua Male/Fer Black/W	ht (g) age (wk) ge (day) I age (wk) male
Figu	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex 2/1 Race 3/0	tudy #1.	Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	ht (g) age (wk) ge (day) l age (wk) male
 Patients w single dos 	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex 2/1 Race 3/0 Paracteristics (at first blood draw) in S Ethoo		Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	ht (g) age (wk) ge (day) I age (wk) male
 Patients w single dos -Range Neonates 	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White re 4. Patient baseline ch	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex 2/1 Race 3/0 Paracteristics (at first blood draw) in S Ethoo ide range of ethanol after a taining medication dose ethanol st amount of ethanol in a		Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	ht (g) age (wk) ge (day) I age (wk) male
 Patients wasingle dos -Range Neonates single dos Drug Acetamino Chlorothia 	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White are 4. Patient baseline ch Pere exposed to a wh e of an ethanol contained to a set the set to a s	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex 2/1 Race 3/0 aracteristics (at first blood draw) in S Ethanol after a taining medication dose ethanol after a taining medication dose ethanol in a al Ethanol content (%) 7 0.50		Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	ht (g) age (wk) ge (day) I age (wk) male
Patients w single dos -Range Neonates single dos Range Drug Acetamino Chlorothia: Cyprohepta Dexametha Diazoxide	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White Black/White are 4. Patient baseline ch Gere exposed to a wh e of an ethanol cont 13.1 to 215 mg/kg/ received the greate e from phenobarbit phen with codeine elixir ride oral suspension dine hydrochloride syrup sone oral solution oral suspension	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex 2/1 Race 3/0 aracteristics (at first blood draw) in S Ethoo tide range of ethanol after a taining medication dose ethanol st amount of ethanol in a ad Ethanol content (%) 7 0.50 5 30 7.25		Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	ht (g) age (wk) ge (day) I age (wk) male
 Patients w single dos -Range Neonates single dos Range Meonates single dos Drug Acetamino Chlorothiaz Cyprohepta Diazoxide o Digoxin ora Ferrous sul Griseofulvi 	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White Black/White are 4. Patient baseline ch Gere exposed to a wh e of an ethanol cont 13.1 to 215 mg/kg/ received the greate e from phenobarbit phen with codeine elixir ride oral suspension dine hydrochloride syrup sone oral solution oral suspension	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex 2/1 Race 3/0 aracteristics (at first blood draw) in S Ethool for ange of ethanol after a taining medication dose ethanol st amount of ethanol in a al Ethanol content (%) 7 0.50 5 30	200- 200- 150- 100-	Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	ht (g) age (wk) ge (day) I age (wk) male
 Patients wasingle dos single dos -Range Neonates single dos -Range Neonates single dos Drug Acetamino Chlorothiaz Cyprohepta Dexametha Diazoxide Digoxin or Ferrous sul Griseofulvi Hydroxyzir Lasix oral s Maalox or a solution of the second secon	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White <i>Black/White</i> <i>Refere exposed to a whee of an ethanol content</i> <i>13.1 to 215 mg/kg/</i> <i>received the greate</i> <i>e from phenobarbit</i> ohen with codeine elixir ride oral suspension di solution fate oral drops n oral suspension te hydrochloride syrup	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex 2/1 Race 3/0 aracteristics (at first blood draw) in S Ethood fide range of ethanol after a taining medication dose ethanol st amount of ethanol in a al Ethanol content (%) 7 0.50 5 30 7.25 10 0.20 0.20		Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	ht (g) age (wk) ge (day) I age (wk) male
Patients w single dos -Range Neonates -Range Drug Acetamino Chlorothia Cyprohepta Diazoxide Digoxin ora Ferrous sul Griseofulvi Hydroxyzin Lasix oral s Maalox ora Metoclopra Nystatin or	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i> <i>Black/White</i>	Phenobarbital or Dexamethasone "Ethanol" (n=3)1858 ± 1540.131.1 ± 5.928.3 ± 2.135.2 ± 5.6Sex2/1Race3/0aracteristics (at first blood draw) in SCEthocide range of ethanol after a taining medication 'dose ethanolide range of ethanol after a taining medication 'dose ethanolst amount of ethanol in a cal27 0.505 30 7.250 0.20 0.20 0.55	200- 200- 150- 100-	Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	ht (g) age (wk) ge (day) I age (wk) male
 Patients wasingle dos single dos encarge Neonates single dos encarge Neonates single dos encarge Neonates single dos encarge Drug Acetamino Chlorothiaz Cyprohepta Dexametha Diazoxide encarge Digoxin or encarge Digoxin or encarge Maalox or an Metoclopra Nystatin or Phenobarb Prednisolo Propranolo Ranitidine 	Birth weight (g) Gestational age (wk) Postnatal age (day) Postmenstrual age (wk) Male/Female Black/White Black/White <i>Black/White</i> <i>Refere exposed to a whee of an ethanol content</i> 13.1 to 215 mg/kg/ <i>received the greate</i> <i>e from phenobarbit</i> oben with codeine elixir tide oral suspension dine hydrochloride syrup sone oral solution fate oral suspension i suspension mide oral solution fate oral solution fate oral solution fate oral solution fate oral solution fate oral solution fate oral solution al suspension mide oral solution al suspension tal elixir	Phenobarbital or Dexamethasone "Ethanol" (n=3) 1858 ± 1540.1 31.1 ± 5.9 28.3 ± 2.1 35.2 ± 5.6 Sex 2/1 Race 3/0 Phenobarbital or Dexamethasone Sex 2/1 Race 3/0 Phenobarbital or Dexamethasone Sex 2/1 Phenobarbital or Dexamethasone Sex 2/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/1 Sex 2/2 3/2 3/2 3/2 3/2 3/2 3/2 3/2	200- 200- 150- 100-	Birth weig Gestational a Postnatal a Postmenstrua Male/Fer Black/W Figure 5. Patie	int (g) age (wk) age (wk)



Sample Collection 15 patients 39 points Phenobarbital (oral) **Dexamethasone (oral) Buprenorphine &** 3 patients 2 patients **Phenobarbital*** 2 points 13 points 3 patients 8 points 11 points >LLOQ 0 points >LLOQ 7 points >LLOQ **Blood ethanol levels Blood ethanol levels** ranged from 0.63 to ranged from 0.55 to <u>85.4</u> <u>68.1 mg/L</u> mg/L Figure 8: Plasma sample collection. A total of 39 plasma samples from 15 neonates were collected over the study period. *Eliminated from further analysis due to overlapping medication administration times. **Concentration-Time Profiles** • Ethanol is rapidly eliminated and does not accumulate with the current dosing regimens Phenobarbital Buprenorphine 0.5 mg/L line o reference 750 300 400 0 100 200 300 100 200 Time (min) Time (min) Figure 9: Concentration-time plots for buprenorphine only and phenobarbital only neonates. (A) Breakdown of samples. (B) Concentration time profile for all samples (above and below LLOQ). (C) Dose normalized concentrations of buprenorphine and phenobarbital. **Conclusion & Future Directions**

• Ethanol intake secondary to medication administration varied widely, but was generally low

• Blood ethanol levels in neonates were low and ethanol was eliminated rapidly after a single dose of oral

- All blood ethanol levels were below the American Academy of Pediatrics recommendation following a

Approximately one third of blood ethanol levels were above the European Medicines Agency recommendation following a single dose of an ethanol containing medication

Dr. Marek was supported by National Institutes of Health Postdoctoral training grant no. T32GM008562